Câncer de bexiga: determinantes sociodemográficos e epidemiologia entre 2019 e 2023
DOI:
https://doi.org/10.34119/bjhrv8n2-348Keywords:
câncer de bexiga, epidemiologia, incidência, mortalidade, BrasilAbstract
O câncer de bexiga é considerado a décima neoplasia mais prevalente a nível mundial. A grande maioria dos cânceres de bexiga está associada à exposição ao tabagismo e compostos químicos com potencial carcinogênico. Acredita-se que o maior vínculo entre os homens e o tabaco possa justificar a discrepância de incidência identificada entre os gêneros. A patologia representa um dos principais colaboradores para a carga global de câncer, mesmo considerando a evolução nos métodos diagnósticos e terapêuticos. Esse estudo transversal, de caráter observacional, tem como objetivo determinar o perfil epidemiológico da neoplasia maligna de bexiga e suas variantes sociodemográficas utilizando dados captados no Sistema de Informações Hospitalares (SIH/DATASUS) durante 2019 e 2023. O perfil geral predominante de internamentos, por neoplasia maligna da bexiga, no território brasileiro foi de indivíduos do sexo masculino, com idade entre 60 e 79 anos, de cor/raça branca. Observou-se também que as taxas de mortalidade foram maiores em indivíduos do sexo feminino e de cor/raça preta. Considerando o número elevado de casos associados a fatores ambientais, o câncer de bexiga é um alvo importante para o desenvolvimento de intervenções de saúde pública. A cessação do tabagismo mostrou reduzir o risco de câncer de bexiga e, consequentemente, mitigar o aumento da incidência a nível global.
References
ANDERSSON KE, ARNER A: Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiological Reviews, n.84, p.935-986, 2004.
BANDI P, MINIHAN AK, SIEGEL RL, et al. Updated review of major cancer risk factors and screening test use in the United States in 2018 and 2019, with a focus on smoking cessation. Cancer Epidemiology, Biomarkers and Prevention, n.30, p.1287–99, 2021.
BESSA A, MACLENNAN S, ENTING D, et al. Consensus in bladder cancer research priorities between patients and healthcare professionals using a four-stage modified Delphi Method. European Urology, n.76, p.258–259, 2019.
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Journal for Clinicians, n.68, p.394–424, 2018.
BURGER M, CATTO JW, DALBAGNI G, et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, n.63, p.234–241, 2013.
FREEDMAN ND, SILVERMAN DT, HOLLENBECK AR, et al. Association Between Smoking and Risk of Bladder Cancer Among Men and Women. JAMA, n.306, p.737–745, 2011.
HALASEH SA, HALASEH S, ALALI Y, et al. A Review of the Etiology and Epidemiology of Bladder Cancer: All You Need To Know. Cureus, n.14, 2022.
JACKSON SS, MARKS MA, KATKI HA, et al. Sex disparities in the incidence of 21 cancer types: quantification of the contribution of risk factors. Cancer, n.128, p.3531–3540, 2022.
MARCOS-GRAGERA R, MALLONE S, KIEMENEY LA, et al. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. European Journal of Cancer, n.51, p.2217-2230, 2015.
MCGRATH M, MICHAUD DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. American Journal of Epidemiology, n.163, p.236–244, 2006.
MUSHTAQ J, THURAIRAJA R, NAIR R. Bladder Cancer. Surgery, n.37, p.529–537, 2019.
SATYAL U, SRIVASTAVA A, ABBOSH PH. Urine Biopsy-Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer. Frontiers in Oncology, n.9, p.1266 , 2019.
SIEVERT KD, AMEND B, NAGELE U, et al. Economic aspects of bladder cancer: What are the benefits and costs? World Journal of Urology, n.27, p.295–300, 2009.
SILVERMAN DT, KOUTROS S, FIGUEROA JD, et al. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, n.4, p. 977–92, 2017.
SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer Journal for Clinicians, n.71, p.209-249, 2021.
VAN HEMELRIJCK M, PATEL P, MOUW KW. Editorial: Bladder Cancer - A Cinderella Cancer: Advances and Remaining Research Questions. Frontiers in Oncology, n.10, p.1749, 2020.
WHELAN P, BRITTON JP, DOWELL AC. Three-year follow-up of bladder tumours found on screening . British Journal of Urology, n. 72, p.893-896, 1993.
WOLFF I, BROOKMAN-MAY S, MAY M. Sex difference in pres entation and outcomes of bladder cancer: Biological reality or statistical fluke? Current Opinion in Urology, n.25, p.418-426, 2015.
Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GE, USA, 2010.
International Agency for Research on Cancer. Improving Early Detection and Clinical Management of Bladder Cancer-A promising urine test (uTERTpm). IARC Evidence Summary Brief No. 3, 2022.
